Iron-salicylate complex induces peroxidation, alters hepatic lipid profile and affects plasma lipoprotein composition.
Iron overload, with its associated toxic effects, has serious health consequences and results in damage to the liver, heart and other organs. Salicylate may be used as the lipophilic carrier, transporting more iron into hepatocytes. In this study, we examined the effect of the combined administration of these compounds on plasma lipid profile and lipoprotein composition, as well as on hepatic lipid concentration. Male Spraque-Dawley rats were injected i.p. with Fe (15 mg/kg weight). This injection was repeated 24 h later with a gavage of sodium salicylate (700 mg/kg). Control rats received 0.9% NaCl only. The peroxidation indices TBARS (P < 0.001) and conjugated dienes (P < 0.05) significantly increased in the blood (50 and 122%, respectively) and liver (333 and 101%, respectively) of Fe salicylate-treated rats. Concomitantly, blood and liver arachidonic acid content was diminished by iron treatment. In parallel, the plasma lipid profile was markedly affected in Fe-salicylate treated-rats. Lower plasma concentrations of total cholesterol (25%, P < 0.0001) cholesteryl ester, (34%, P < 0.001) and high-density lipoprotein-cholesterol (50%, P < 0.001) were observed. Lipoprotein composition analysis revealed enrichment of free cholesterol and depletion of cholesterol ester in very low-density, intermediate-density, low-density and high-density (HDL2, HDL3) lipoproteins. Furthermore, SDS-polyacrylamide gel electrophoresis revealed several alterations in the apolipoprotein distribution of these lipoproteins. The activity of lecithin:cholesterol acyltransferase was unchanged and could not account for the reduction of cholesterol esterification. As for the plasma, the liver exhibited a significant (P < 0.001) decrease in total cholesterol (2.42 +/- 0.07 versus 1.89 +/- 0.06 mg/g liver), essentially due to a reduction in cholesteryl ester (0.93 +/- 0.07 versus 0.51 +/- 0.03 mg/g, P < 0.001). Again, the activity of ACAT (dpm/mg microsomal protein) was not lower (12,700 +/- 1250) than that of controls (9650 +/- 1080). Thus, the iron-salicylate was able to induce peroxidation and to profoundly affect the intravascular and intrahepatic lipid, and plasma lipoprotein metabolism. Additional work is needed to elucidate the mechanisms involved in the underlying lipid and lipoprotein abnormalities.
Brunet
S
S
Department of Nutrition, Hopital Sainte-Justine, Université de Montreal, Quebec, Canada.
Guertin
F
F
Thibault
L
L
Gavino
V
V
Delvin
E
E
Levy
E
E
D000818:Animals; D001663:Bilirubin / Q000097:blood; D002784:Cholesterol / Q000097:blood; D002788:Cholesterol Esters / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D005227:Fatty Acids / Q000032:analysis; D006801:Humans; D007501:Iron / Q000494:pharmacology* / Q000633:toxicity; D019190:Iron Overload / Q000378:metabolism*; D015227:Lipid Peroxidation / Q000187:drug effects*; D008074:Lipoproteins / Q000097:blood*; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012980:Sodium Salicylate / Q000494:pharmacology*; D002785:Sterol O-Acyltransferase / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis
D002788:Cholesterol Esters; D008076:Cholesterol, HDL; D005227:Fatty Acids; D008074:Lipoproteins; D017392:Thiobarbituric Acid Reactive Substances; D002784:Cholesterol; D007501:Iron; D002785:Sterol O-Acyltransferase; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; D001663:Bilirubin; D012980:Sodium Salicylate